How Does Medical Device Reimbursement Work? A No-Fluff Primer for MedTech Founders

2026-07-27 · Caduvo Team

A plain-language primer on how medical device reimbursement actually works in the US: CPT versus HCPCS codes, Medicare and commercial payer coverage, and why reimbursement strategy must start before you freeze your device design.

The moment a clinician decides to use your device, someone has to pay for it. If you cannot answer how that happens—with a specific code, a coverage pathway, and a dollar amount—you are not building a business. You are building a science project. Most founders learn the coding-coverage-payment sequence too late, after design choices have already locked them into a reimbursement dead end. This primer walks through the mechanics and explains why reimbursement strategy belongs in the same conversation as design controls and regulatory pathway.

The Three-Legged Stool: Coding, Coverage, Payment

Reimbursement is not one thing. You need all three pieces to work, and they are sequential.

  1. Coding — What was done and with what device. Codes translate the procedure and the product into a language payers can process.
  2. Coverage — Will the payer pay for it. Coverage decisions define the clinical circumstances under which a code becomes payable.
  3. Payment — How much they pay. Payment attaches a dollar amount to the covered code.

Miss any leg and the stool falls. A code with no coverage policy is just a number. Coverage with no payment rate is a theoretical promise. A device cleared by FDA with no code at all is invisible to the billing system. This is why device reimbursement cannot be a post-launch task. The oldest advice in MedTech market access is still the truest: code first, then coverage, then payment.

CPT Codes vs. HCPCS Codes: Own the Right One Early

The difference between HCPCS vs CPT codes shapes your entire launch timeline. For most physician-administered procedures, you want a Category I CPT code. That requires a rigorous application to the American Medical Association with published clinical data. The process takes 12 to 18 months from application submission, and you cannot apply without a cleared device and meaningful peer-reviewed evidence. A temporary Category III code might bridge the gap, but many commercial payers refuse to pay on Category III codes—a hard lesson startups learn after months of denials.

Durable medical equipment, prosthetics, and certain supplies fall under HCPCS Level II. What is an HCPCS code? A five-character alphanumeric code maintained by CMS. The application cycle opens quarterly, and the bar for clinical evidence has risen sharply in the past three years. If your device walks a line between a procedural CPT and a product-level HCPCS, get expert input before you commit to a clinical trial design. The evidence required for a successful CPT application differs from what CMS expects for a HCPCS Level II request, and re-running a study because you picked the wrong target is an expensive mistake.

Medicare vs. Commercial Payers: The Coverage Architectures Differ

Medicare medical device reimbursement operates on a predictable architecture of National Coverage Determinations and Local Coverage Determinations. An NCD is binding nationwide. An LCD governs a specific MAC jurisdiction. If there is no NCD and no LCD, coverage defaults to the MAC’s discretion—meaning 12 regional contractors can make 12 different calls on the same device. You need to read the Medicare Coverage Database for every jurisdiction where you expect claims volume. This is not a one-time search. LCDs get revised, often quietly, and a proposed LCD that restricts your category can strand your pipeline.

Commercial payers are a different animal. There are thousands of them, each with its own medical policy committee. Most follow Medicare’s lead on major coverage questions, but they add proprietary prior authorization requirements, site-of-service restrictions, and health-plan-specific medical necessity criteria. A common pattern: a startup secures Medicare coverage through an LCD, then spends 18 exhausting months securing individual commercial contracts one by one. Early evidence designed with value analysis committee priorities—comparative cost data, length-of-stay impact, readmission reduction—shortens that 18 months appreciably.

Why Reimbursement Strategy Starts Before Design Freeze

The device’s physical form factor, the clinical workflow it requires, and the patient population it serves all become reimbursement inputs the moment you freeze design. A few examples:

Each of those decisions gets baked into the device before any regulatory submission. Retroactively adding a feature to catch a code often means a new 510(k) or even a separate clinical study. Reimbursement feasibility should be a gate criterion at the design review. Three questions to ask:

  1. Does a distinct code already exist for the work this device does?
  2. If we need a new code, what is the absolute minimum clinical evidence required to get it?
  3. Who pays for this category of device today, and what is their average payment rate?

Answer those before you finalize the DFM review. If you cannot answer them with confidence, call a halt and get the data.

Checklist: What Founders Can Do This Quarter

Do not hand this to an intern. The reimbursement data you gather in the next 90 days will shape your Series A narrative and your clinical trial endpoints.

Actionable Takeaways

Related reading